Verrica Pharmaceuticals Inc. is a therapeutics company focused on developing and commercializing medications for dermatologic diseases, including skin cancers. The company's commercial product, YCANTH (VP-102), approved by the FDA in July 2023 for molluscum contagiosum, generated $15.3 million in net product revenue for the year ended December 31, 2025, compared to $6.6 million in 2024. This increase was primarily due to higher deliveries of YCANTH to distribution partners. License and collaboration revenue significantly increased to $20.3 million in 2025 from $1.0 million in 2024, driven by milestone payments from Torii Pharmaceutical related to YCANTH's approval in Japan and commercial supply activity.
Verrica's financial performance also saw a decrease in operating expenses, totaling $47.8 million in 2025 compared to $73.5 million in 2024. Selling, general, and administrative expenses decreased from $58.8 million to $35.2 million, primarily due to reduced commercial activities and personnel costs following a restructuring. Research and development expenses also decreased from $11.8 million to $8.9 million, mainly due to lower clinical costs for VP-315, although this was partially offset by increased costs related to the Phase 3 program for YCANTH in common warts. Despite these improvements, the company reported a net loss of $17.9 million for 2025, a significant decrease from the $76.6 million loss in 2024.
Operationally, Verrica achieved several milestones, including Torii Pharmaceutical receiving approval for YCANTH (TO-208) in Japan and positive feedback from the European Medicines Agency supporting a Marketing Authorization Application for YCANTH in the European Union. The company also initiated a global Phase 3 clinical program for YCANTH in common warts, with the first patient dosed in December 2025. Furthermore, Verrica presented additional data on VP-315, highlighting its potential as a non-surgical immunotherapy treatment for basal cell carcinoma.
Looking ahead, Verrica faces challenges related to its financial position, as it has concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these financial statements are issued. The company plans to address this by seeking additional funding through various means, including equity offerings, debt financing, and strategic partnerships. Verrica is focusing its efforts on commercializing YCANTH for molluscum, developing YCANTH for common warts, and advancing VP-315 for basal cell carcinoma, while also exploring non-dilutive partnerships to fund development and commercialization efforts. As of December 31, 2025, Verrica had 76 full-time employees.
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals develops dermatology treatments, including FDA-approved YCANTH (VP-102) for molluscum contagiosum, a contagious skin disease. The company focuses on clinician-administered therapies for high unmet needs, with pipeline products targeting common warts and dermatologic cancers like basal cell carcinoma. Its business model emphasizes innovative formulations, strategic licensing, and commercialization through specialized sales, targeting healthcare providers and patients worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.